keyword
MENU ▼
Read by QxMD icon Read
search

Subutex

keyword
https://www.readbyqxmd.com/read/26811236/use-of-an-acetyl-derivative-to-improve-gc-ms-determination-of-norbuprenorphine-in-the-presence-of-high-concentrations-of-buprenorphine-in-urine
#1
Joel R Gervais, Gregory A Hobbs
Certain patients being treated with Suboxone™ or Subutex™ can exhibit very high buprenorphine and low norbuprenorphine concentrations in urine. Very high buprenorphine can interfere with buprenorphine-D4 used as an internal standard, causing errors in norbuprenorphine determination by gas chromatography-mass spectrometry (GC-MS). We used a modified method of Wu et al. to introduce norbuprenorphine-D3 as a separate internal standard for norbuprenorphine. This allowed us to accurately measure norbuprenorphine in neat urine specimens when buprenorphine is present in extremely high concentrations...
April 2016: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/26479717/population-pharmacokinetic-modeling-after-repeated-administrations-of-rbp-6000-a-new-subcutaneously-injectable-long-acting-sustained-release-formulation-of-buprenorphine-for-the-treatment-of-opioid-use-disorder
#2
Celine M Laffont, Roberto Gomeni, Christian Heidbreder, J P Jones, Azmi F Nasser
RBP-6000 is a novel sustained-release formulation of buprenorphine for the treatment of opioid use disorder, which has been designed for once-monthly (28 days) subcutaneous (SC) injections. A population pharmacokinetic (PK) model was developed to describe the time course of buprenorphine plasma concentrations after repeated SC injections of RBP-6000 at 50 mg, 100 mg, 200 mg, or 300 mg in treatment-seeking opioid-dependent subjects previously on sublingual buprenorphine (Subutex(®) ) treatment. The μ-opioid receptor occupancy was predicted using a previously developed PK/PD Emax model...
July 2016: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/25474108/crushed-and-injected-buprenorphine-tablets-characteristics-of-princeps-and-generic-solutions
#3
Régis Bouquié, Laura Wainstein, Paul Pilet, Jean-Marie Mussini, Guillaume Deslandes, Johann Clouet, Eric Dailly, Pascale Jolliet, Caroline Victorri-Vigneau
Self-injection of high-dose buprenorphine is responsible for well-described complications. In 2011, we have been alerted by unusual but serious cutaneous complication among injection buprenorphine users. A prospective data collection identified 30 cases of necrotic cutaneous lesions after injection of filtered buprenorphine solution, among which 25 cases occurred following injection of buprenorphine generics. The main goal of our study was to put forward particularities that could explain the cutaneous complications, by qualitatively and quantitatively confronting particles present in Subutex and generics solutions...
2014: PloS One
https://www.readbyqxmd.com/read/25212472/-psychopathology-of-the-misuse-of-subutex%C3%A2-the-popeye-syndrome
#4
J Békaert, G Podevin
INTRODUCTION: High dose buprenorphine (HDB), commonly known as Subutex(®), is nowadays largely prescribed as a replacement therapy for major opiate dependence. Its sublingual administration allows a decrease in the withdrawal syndrome accompanying opiate abuse cessation. Over the past few decades, epidemiological data on people on replacement therapy have emphasized an increase in the misuse of Subutex(®) and more specifically intravenous injections of HDB. These growing practices pave the way to major physical consequences or even death...
June 2015: L'Encéphale
https://www.readbyqxmd.com/read/25069011/a-naturalistic-comparison-of-the-effectiveness-of-methadone-and-two-sublingual-formulations-of-buprenorphine-on-maintenance-treatment-outcomes-findings-from-a-retrospective-multisite-study
#5
MULTICENTER STUDY
Steven L Proctor, Amy L Copeland, Albert M Kopak, Philip L Herschman, Nadiya Polukhina
OBJECTIVE: This study sought to compare the effectiveness of the 3 most commonly prescribed maintenance medications in the United States indicated for the treatment of opioid dependence in reducing illicit drug use and retaining patients in treatment. METHOD: Data were abstracted from electronic medical records for 3,233 patients admitted to 34 maintenance treatment facilities located throughout the United States during the period of July 1, 2012, through July 1, 2013...
October 2014: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/24985936/perioperative-management-of-a-patient-undergoing-clagett-window-closure-stabilized-on-suboxone%C3%A2-for-chronic-pain-a-case-report
#6
Alexander Huang, Rita Katznelson, Marc de Perrot, Hance Clarke
PURPOSE: Buprenorphine is a semisynthetic opioid with both agonist and antagonist activity at the opioid receptor. Currently, buprenorphine is commonly available in sublingual preparations combined with naloxone (e.g., Suboxone®, Subutex®). There has been increased use of buprenorphine derivatives in the areas of substance addiction and chronic pain. Nevertheless, there is limited and conflicting information in the literature pertaining to the optimal management of buprenorphine-stabilized patients presenting for surgery...
September 2014: Canadian Journal of Anaesthesia, Journal Canadien D'anesthésie
https://www.readbyqxmd.com/read/24820178/designing-a-tool-allowing-for-a-standardized-assessment-of-resistance-to-drug-diversion
#7
Caroline Victorri-Vigneau, Cedric Collin, Catherine Messina-Gourlot, Christel Raffournier, Michel Mallaret, Jérôme Besse, Marie-Anne Courne, Nathalie Richard, Véronique Sébille, Philippe Arnaud
OBJECTIVES: Drug diversion is a growing problem in numerous countries. Some laboratories have developed tamper-resistant formulations. The problem for healthcare authorities is now to assess new formulations developed to limit the risk of diversion for administration by another mode and intended mode. It would be helpful to have a pertinent panel of in vitro tests allowing assessment of how a formulation may be altered, both for healthcare authorities and for laboratories, so as to implement adequate sanitary measures...
July 2014: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/24099717/disaccharides-in-urine-samples-as-markers-of-intravenous-abuse-of-methadone-and-buprenorphine
#8
Hilke Jungen, Hilke Andresen-Streichert, Alexander Müller, Stefanie Iwersen-Bergmann
Methadone and buprenorphine are commonly used as oral substitutes in opiate maintenance programs to treat persons who are dependent on heroin. During these programs, patients are not allowed to continue using illicit drugs. Abstinence can easily be monitored by urine tests with immunochemical methods. It is well known that the intravenous abuse of heroin substitutes like methadone or buprenorphine has become common as well. The methadone-prescribing physician has no opportunity to check whether the opiate maintenance treatment patient takes his substitution medicines orally as intended or continues with his intravenous misuse now substituting the methadone instead of injecting heroin...
November 2013: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/23849373/buprenorphine-therapy-an-increasing-challenge-in-oral-and-maxillofacial-surgery
#9
REVIEW
Michael Wasson, O Ross Beirne
Suboxone is a 4:1 mixture of buprenorphine and naloxone and Subutex is buprenorphine alone. The high affinity μ-receptor binding of buprenorphine (Suboxone and Subutex) renders other opioids ineffective. Inadequate procedural sedation, inadequate analgesia, and significant drug interactions complicate the treatment of patients taking Suboxone or Subutex. Careful planning and an understanding of buprenorphine pharmacology can minimize potential perioperative complications in patients taking Suboxone or Subutex...
August 2013: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/23772177/comment-on-a-comparison-of-buprenorphine-naloxone-to-buprenorphine-and-methadone-in-the-treatment-of-opioid-dependence-during-pregnancy-maternal-and-neonatal-outcomes
#10
Robert G Newman, Susan G Gevertz
In a recent article, Lund et al sought to compare maternal and neonatal outcomes of various treatment regimens for opioid dependence during pregnancy.1 In their background, discussion the authors state that "In the United States buprenorphine plus naloxone [Suboxone(®)] … has been the preferred form of prescribed buprenorphine due to its reduced abuse liability relative to buprenorphine alone [Subutex(®)]." This claim is certainly consistent with the view of the firm that has manufactured and sold both products, Reckitt Benckiser...
2013: Substance Abuse: Research and Treatment
https://www.readbyqxmd.com/read/23697094/basic-epidemiology-of-opiate-misuse-substitution-treatment-in-belgium
#11
Y Ledoux
The Substitution Treatment National Registry provided from mid 2006 till mid 2009 an exhaustive documentation on all patients being prescribed methadone or buprenorphine in Belgium. This endeavour was possible through cooperation of all community pharmacies and their representative organizations was supported at the time by the former Health federal minister. The Liberal belgian opiate medical substitution process authorizes untill now de facto any doctor to prescribe methadone and pharmacists are supported to dispense it...
September 2012: Journal de Pharmacie de Belgique
https://www.readbyqxmd.com/read/23344700/emergency-department-visits-and-hospitalizations-for-buprenorphine-ingestion-by-children-united-states-2010-2011
#12
(no author information available yet)
Buprenorphine (Subutex) and buprenorphine/naloxone (Suboxone) received Food and Drug Administration approval in 2002 for the treatment of opioid dependence. Introduction of these drugs expanded the availability of opioid-dependence treatment options to reduce the morbidity and mortality associated with opioid abuse, and buprenorphine has become an increasingly prescribed component of office-based treatment. However, unsupervised ingestion of buprenorphine-containing products by children is a growing concern...
January 25, 2013: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/22370011/-subutex-is-safe-perceptions-of-risk-in-using-illicit-drugs-during-pregnancy
#13
Anna Leppo
BACKGROUND: The dominant biomedical discourse stresses the physiological risks to the foetus or newborn posed by the prenatal use of illicit drugs. There is also a strong moral incentive for pregnant women to abstain from drugs. Yet few researchers have explored how pregnant, drug-using women themselves perceive the risks involved. The present paper investigates the reasoning by women about risks involved in prenatal drug use. Theoretically, a socio-cultural approach to risk is taken...
September 2012: International Journal on Drug Policy
https://www.readbyqxmd.com/read/21948099/can-the-chronic-administration-of-the-combination-of-buprenorphine-and-naloxone-block-dopaminergic-activity-causing-anti-reward-and-relapse-potential
#14
Kenneth Blum, Thomas J H Chen, John Bailey, Abdalla Bowirrat, John Femino, Amanda L C Chen, Thomas Simpatico, Siobhan Morse, John Giordano, Uma Damle, Mallory Kerner, Eric R Braverman, Frank Fornari, B William Downs, Cynthia Rector, Debmayla Barh, Marlene Oscar-Berman
Opiate addiction is associated with many adverse health and social harms, fatal overdose, infectious disease transmission, elevated health care costs, public disorder, and crime. Although community-based addiction treatment programs continue to reduce the harms of opiate addiction with narcotic substitution therapy such as methadone maintenance, there remains a need to find a substance that not only blocks opiate-type receptors (mu, delta, etc.) but also provides agonistic activity; hence, the impetus arose for the development of a combination of narcotic antagonism and mu receptor agonist therapy...
December 2011: Molecular Neurobiology
https://www.readbyqxmd.com/read/21768940/pharmacokinetics-of-buprenorphine-a-comparison-of-sublingual-tablet-versus-liquid-after-chronic-dosing
#15
Peggy Compton, Walter Ling, C Nora Chiang, David E Moody, Alice Huber, Debbie Ling, Charles Charuvastra
Although buprenorphine is approved for use in the outpatient treatment of opioid addiction in 2 tablet formulations, a monoproduct containing buprenorphine only (Subutex) and a buprenorphine/naloxone combination product (Suboxone), much of the clinical data that support the approval by the U.S. Food and Drug Administration were generated by using a sublingual liquid. To interpret the literature in prescribing parameters for tablet buprenorphine, this study was designed to determine steady state buprenorphine plasma levels for the 2 formulations and to assess the relative bioavailability of each...
June 2007: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/21124750/buprenorphine-a-relatively-new-treatment-for-opioid-dependence
#16
Christopher Welsh, Adela Valadez-Meltzer
Opioid dependence is a significant and growing problem in the United States. For nearly a century, federal regulations have made it illegal for psychiatrists and other physicians to pharmacologically manage this condition in an office-based setting using opioids. The passage of the Drug Addiction Treatment Act of 2000 has made it possible for all physicians to prescribe buprenorphine to patients in such a setting. Buprenorphine, a partial mu-opoid receptor agonist, has unique pharmacologic properties that distinguish it from methadone and other medications used in the treatment of opioid dependence...
December 2005: Psychiatry
https://www.readbyqxmd.com/read/21112758/the-prevalence-and-correlates-of-buprenorphine-inhalation-amongst-opioid-substitution-treatment-ost-clients-in-australia
#17
Danielle Horyniak, Paul Dietze, Briony Larance, Adam Winstock, Louisa Degenhardt
BACKGROUND: Diversion and injection of buprenorphine (Subutex(®)) and buprenorphine-naloxone (Suboxone(®)) have been well documented. Recent international research and local anecdotal evidence suggest that these medications are also used by other routes of administration, including smoking and snorting. METHODS: A cross-sectional sample of 440 opioid substitution treatment (OST) clients was recruited through pharmacies and clinics in three Australian jurisdictions, and interviewed face-to-face using a structured questionnaire...
March 2011: International Journal on Drug Policy
https://www.readbyqxmd.com/read/21074741/anesthesia-for-patients-on-buprenorphine
#18
REVIEW
Ethan O Bryson, Scott Lipson, Clifford Gevirtz
Opioid abuse is a devastating, costly, and growing problem in the United States, and one for which treatment can be complicated by barriers such as access to care and legal issues. Only 12% to 15% of the opioid-dependent population is enrolled in methadone maintenance programs. A significant breakthrough occurred with passage of the Drug Addiction Treatment Act of 2000 (DATA 2000). For the first time in approximately 80 years, physicians could legally prescribe opioid medications for the treatment of opioid addiction...
December 2010: Anesthesiology Clinics
https://www.readbyqxmd.com/read/20958853/buprenorphine-based-regimens-and-methadone-for-the-medical-management-of-opioid-dependence-selecting-the-appropriate-drug-for-treatment
#19
REVIEW
Icro Maremmani, Gilberto Gerra
Maintenance therapy with methadone or buprenorphine-based regimens reduces opioid dependence and associated harms. The perception that methadone is more effective than buprenorphine for maintenance treatment has been based on low buprenorphine doses and excessively slow induction regimens used in early buprenorphine trials. Subsequent studies show that the efficacy of buprenorphine sublingual tablet (Subutex®) or buprenorphine/naloxone sublingual tablet (Suboxone®) is equivalent to that of methadone when sufficient buprenorphine doses, rapid induction, and flexible dosing are used...
November 2010: American Journal on Addictions
https://www.readbyqxmd.com/read/20699077/-buprenorphine-for-the-treatment-of-opioid-dependence-a-study-on-generic-substitution-conducted-in-community-pharmacies
#20
MULTICENTER STUDY
Gaëlle Julians-Minou, Sarah Bruch, Nathalie Peyre, Guillaume Sudérie, Maryse Lapeyre-Mestre, Anne Roussin
OBJECTIVE: To describe the evolution of buprenorphine prescription form characteristics before and after the application of a measure of the French Social Security system aimed to encourage the use of generic drugs. METHOD: All buprenorphine prescription forms issued to sixty-two patients subjected to follow-up in 6 community pharmacies were analysed between October 2007 and February 2008. RESULTS: Patients maintained on Subutex during the whole follow-up were more numerous (n=39), younger, and received a higher daily dose of buprenorphine (10...
May 2010: Thérapie
keyword
keyword
13309
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"